Sudeep Pharma (BOM:544619) Research & Development: ₹0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:544619 Sudeep Pharma Ltd BOM:544619
18 GF Score
Price ₹868.55
! 5 Warning Signs
View Full Analysis

What is Sudeep Pharma Research & Development?

Sudeep Pharma BOM:544619 -1.10% 18 Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus rates BOM:544619 with a GF Score™ of 18/100. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Sudeep Pharma's Research & Development for the three months ended in Mar. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Sudeep Pharma  (BOM:544619) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Sudeep Pharma Research & Development Related Terms

Sudeep Pharma Research & Development Historical Data

* Premium members only.

The historical data trend for Sudeep Pharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sudeep Pharma Research & Development Chart

Sudeep Pharma Annual Data
Trend Mar23 Mar24 Mar25 Mar26
Research & Development
0.00 0.00 0.00 0.00

Sudeep Pharma Quarterly Data
Mar23 Mar24 Dec24 Mar25 Jun25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
BOM:544619
18GF Score
Sudeep Pharma Ltd BOM:544619
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sudeep Pharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
Sudeep Pharma (BOM:544619) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Sudeep Pharma and its competitors.
Is Sudeep Pharma's Research & Development too high?
Sudeep Pharma's current Research & Development is ₹0 Mil. Overall, Sudeep Pharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sudeep Pharma's Research & Development compare to ZTS?
Sudeep Pharma's Research & Development of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Sudeep Pharma and its competitors. Sudeep Pharma's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sudeep Pharma stock overvalued right now?
Sudeep Pharma (BOM:544619) has a current Research & Development of ₹0 Mil. The current Research & Development is ₹0 Mil. Sudeep Pharma's overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Sudeep Pharma (BOM:544619), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sudeep Pharma Business Description

Other Exchanges SUDEEPPHRM:India
Address Gotri-Sevasi Road, 601-602, 6th floor, Sears II, East Wing, Towers - 2, Sevasi, Vadodara, GJ, IND, 391101
Sudeep Pharma Ltd is a technology led manufacturer of excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries and is dedicated to contributing to the healthcare ecosystem. The company operates in two business verticals: Pharmaceutical, food, and nutrition. It focuses on providing refined, mineral-based single ingredients essential to the pharmaceutical, food, and nutrition industries and Specialty ingredients: It pertains manufacturing of specialty ingredients using advance technology solutions. The maximum revenue is generated from the Pharmaceutical, food, and nutrition segment. Geographically, it has presence in the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific.
18GF Score

Get the complete analysis for BOM:544619

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹868.55
Price